Overview

Ivermectin Nasal Drops in Post COVID Parosmia

Status:
Not yet recruiting

Trial end date:
2022-12-01

Target enrollment:
0

Participant gender:
All

Summary

The current study will be a pilot study for a randomized controlled trial conducted on patients recruited from the outpatient clinic of the Otorhinolaryngology Department, Menoufia Faculty of Medicine To evaluate the effect of ivermectin nasal drops in the treatment of post COVID 19 parosmia

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Menoufia University

Treatments:

Budesonide
Ivermectin

Criteria

Inclusion Criteria:

- Patients should be more than 18 years old,

- Patients having a history of COVID 19 infection more than three months ago as
confirmed by PCR test,

- Patients having a post COVID parosmia,

- Patients having no history of systemic steroid administration over the last one month.

Exclusion Criteria:

- History of previous nasal surgery,

- Underlying systemic diseases (like diabetes mellitus, hypertension, or autoimmune
diseases),

- Hypersensitivity to Ivermectin.